Oarsman Capital’s Avanos Medical AVNS Stock Holding History

Oarsman Capital’s Portfolio AVNS Stock Details AVNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-35	Closed	-$557	–	283
2024 Q4	$557	Hold	35	–	–	﹤0.01%	886
2024 Q3	$841	Buy	+35	New	+$800	﹤0.01%	884

Other funds holding AVNS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PIM

Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oarsman Capital's AVNS Position: Q1 2025 in Review

Oarsman Capital sold out of Avanos Medical (AVNS) in Q1 2025, closing a stake of 35 shares — an estimated $557 sold.

Oarsman Capital first reported a position in AVNS in Q3 2024 and held it in 2 quarters. The position peaked at $841 in Q3 2024. 277 funds tracked by Wall St. Rank hold AVNS as of Q1 2025.

Oarsman Capital reported no remaining Avanos Medical position as of Q1 2025 after selling out during the quarter.
Oarsman Capital sold 35 Avanos Medical shares in Q1 2025, an estimated $557.
Oarsman Capital first reported a position in Avanos Medical in Q3 2024 and held it in 2 quarters.
Oarsman Capital's Avanos Medical position peaked at $841 in Q3 2024.
277 funds tracked by Wall St. Rank held Avanos Medical as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.